X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (43) 43
humans (41) 41
index medicus (41) 41
female (39) 39
male (39) 39
middle aged (37) 37
aged (35) 35
chemotherapy (34) 34
cancer (28) 28
adult (25) 25
fluorouracil (20) 20
cisplatin (17) 17
clinical trials (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
medicine & public health (16) 16
metastasis (16) 16
survival (16) 16
treatment outcome (16) 16
5-fluorouracil (14) 14
drug combinations (13) 13
stomach cancer (13) 13
stomach neoplasms - drug therapy (12) 12
trial (12) 12
colorectal cancer (11) 11
gastric cancer (11) 11
neoplasm staging (11) 11
research (11) 11
analysis (10) 10
antimitotic agents (10) 10
antineoplastic agents (10) 10
antineoplastic agents - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
carcinoma (10) 10
care and treatment (10) 10
disease-free survival (10) 10
japan (10) 10
oxaliplatin (10) 10
therapy (10) 10
cancer therapies (9) 9
fluorouracil - administration & dosage (9) 9
irinotecan (9) 9
oxonic acid - administration & dosage (9) 9
patients (9) 9
pharmacology & pharmacy (9) 9
retrospective studies (9) 9
supportive care (9) 9
tegafur - administration & dosage (9) 9
tumors (9) 9
adenocarcinoma - drug therapy (8) 8
aged, 80 and over (8) 8
cisplatin - administration & dosage (8) 8
esophageal cancer (8) 8
medical colleges (8) 8
medical research (8) 8
oxonic acid - adverse effects (8) 8
pharmacology/toxicology (8) 8
prognosis (8) 8
stomach neoplasms - pathology (8) 8
tegafur - adverse effects (8) 8
camptothecin - analogs & derivatives (7) 7
chemoradiotherapy (7) 7
esophagus (7) 7
leucovorin (7) 7
oncology, experimental (7) 7
surgical oncology (7) 7
1st-line treatment (6) 6
antimetabolites, antineoplastic - adverse effects (6) 6
antineoplastic agents - adverse effects (6) 6
bevacizumab (6) 6
cancer research (6) 6
capecitabine (6) 6
colorectal neoplasms - drug therapy (6) 6
colorectal neoplasms - pathology (6) 6
deoxycytidine - administration & dosage (6) 6
deoxycytidine - analogs & derivatives (6) 6
hematology, oncology and palliative medicine (6) 6
kaplan-meier estimate (6) 6
multicenter (6) 6
original (6) 6
surgery (6) 6
survival analysis (6) 6
toxicity (6) 6
adenocarcinoma - pathology (5) 5
antimetabolites, antineoplastic - administration & dosage (5) 5
antitumor-activity (5) 5
asian continental ancestry group (5) 5
camptothecin - administration & dosage (5) 5
combination (5) 5
development and progression (5) 5
drug therapy (5) 5
esophageal neoplasms - therapy (5) 5
fluorouracil - adverse effects (5) 5
follow-up studies (5) 5
gastroenterology & hepatology (5) 5
iii trial (5) 5
leucovorin - administration & dosage (5) 5
medicine, experimental (5) 5
metastases (5) 5
neoplasm metastasis (5) 5
s-1 (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10041, pp. 248 - 257
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2011, Volume 29, Issue 6, pp. 1449 - 1458
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) of the digestive system. Clinical data from 258 patients with... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 3, pp. 684 - 690
Purpose In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage... 
Radiology | Hematology, Oncology and Palliative Medicine | Esophageal squamous cell carcinoma | Long-term toxicity | Salvage surgery | Chemoradiotherapy | SURGERY | SURVIVAL | THORACIC ESOPHAGUS | CANCER | CHEMOTHERAPY | SALVAGE ESOPHAGECTOMY | RADIATION-THERAPY | ONCOLOGY | CHEMORADIATION | RADIOTHERAPY | DEFINITIVE CHEMORADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Chemoradiotherapy - adverse effects | Age Factors | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Carcinoma, Squamous Cell - mortality | Fluorouracil - administration & dosage | Esophageal Neoplasms - mortality | Adult | Female | Surveys and Questionnaires | Esophageal Neoplasms - therapy | Radiotherapy Dosage | Chemoradiotherapy - methods | Drug Administration Schedule | Carcinoma, Squamous Cell - therapy | Survival Rate | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Health Status | Neoplasm Staging | Salvage Therapy - methods | Preoperative Care - methods | Medical colleges | Chemotherapy | Squamous cell carcinoma | Information services | Clinical trials | Esophageal cancer | Information services industry | Cisplatin | Cancer | Fluorouracil | Index Medicus | ESOPHAGUS | DIGESTIVE SYSTEM | COMPLEXES | HETEROCYCLIC COMPOUNDS | DEATH | INFUSION | MEDICINE | AZINES | ANTIMETABOLITES | FLUOROURACILS | IRRADIATION | ORGANIC HALOGEN COMPOUNDS | HYDROXY COMPOUNDS | THERAPY | DRUGS | RADIOLOGY AND NUCLEAR MEDICINE | PNEUMONITIS | ORGANIC NITROGEN COMPOUNDS | COMBINED THERAPY | RADIOLOGY | URACILS | NEOPLASMS | ORGANIC COMPOUNDS | ORGANIC FLUORINE COMPOUNDS | INTAKE | PYRIMIDINES | TOXICITY | SYMPTOMS | TRANSITION ELEMENT COMPLEXES | PLATINUM COMPLEXES | NUCLEAR MEDICINE | ORGANS | SURVIVAL TIME | DISEASES | CARCINOMAS | NAUSEA | BODY
Journal Article
Cancer Science, ISSN 1347-9032, 07/2015, Volume 106, Issue 7, pp. 883 - 890
Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent... 
phase II/III | elpamotide | Advanced pancreatic cancer | peptide vaccine | immunotherapy | Peptide vaccine | Elpamotide | Immunotherapy | Phase II/III | PLUS GEMCITABINE | 1ST-LINE TREATMENT | ENDOTHELIAL-GROWTH-FACTOR | FACTOR RECEPTOR-2 | EPITOPE-PEPTIDES | METASTATIC COLORECTAL-CANCER | CELL LUNG-CANCER | ONCOLOGY | POOR-PROGNOSIS | III TRIAL | COOPERATIVE-ONCOLOGY-GROUP | Adenocarcinoma - pathology | Carcinoma, Adenosquamous - pathology | Double-Blind Method | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Peptide Fragments - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Adenosquamous - drug therapy | Male | Treatment Outcome | Adenocarcinoma - drug therapy | Pancreatic Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Adenosquamous - mortality | Adult | Female | Aged | Pancreatic Neoplasms - mortality | Vascular Endothelial Growth Factor Receptor-2 - administration & dosage | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Statistical analysis | Gemcitabine | Peptides | Toxicity | Clinical trials | Metastasis | Radiation therapy | Cancer therapies | Survival | Patients | Blood | Metastases | Angiogenesis | Chemotherapy | Pancreatic cancer | Medical prognosis | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor | Index Medicus | phase II | III | Original
Journal Article